Projects per year
Personal profile
Interests
Cancer Pharmacology
Receptor Pharmacology
Mechanism of Drug Action
Cell Signalling
Cancer Biology
Breast & Ovarian Cancer
Research Statement
Dr Furlong graduated from University College Dublin (UCD) with an honours degree in Pharmacology and PhD in cell biology. Prior to joining QUB, she was a recipient of the Irish Cancer Society career development research fellowship and developed novel research of chemoresistance in ovarian cancer. Since then, Dr Furlong has established a program of research in cancer pharmacology and stratified biomarker development. The primary focus of this research is to elucidate the mechanism of action of anti-neoplastic agents. Current projects include high-content drug screening to identify cytotoxic drug combinations in cancer cells and dissecting the molecular pharmacology of drug targes such as the histone deacetylase 6 (HDAC6) protein. Areas of expertise include researching the mechanism of drug actions and downstream protein signalling in cell models of cancer. This program of research has led to several high impacting publications and include studies of the miR-433 microRNA in chemoresistant ovarian cancer, IHC biomarker analyses and meta-analyse of the MAD2 protein in ovarian cancer prognosis and the polypharmacology of HDAC6. Dr Furlong has received funding from the Irish Cancer Society, the Health Research Board of Ireland, BBSRC and MRC.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Fiona Furlong is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 2 Finished
-
R1818PMY: MRIs (Modified RNA Indicators): next generation gene signature biomarkers
Furlong, F. (PI) & Simpson, D. (CoI)
16/10/2017 → 30/06/2019
Project: Research
-
R1565PMY: B vitamins and NAD metabolism, or when vitamin B3's bioavailability is not enough
Furlong, F. (PI)
25/09/2015 → 30/06/2019
Project: Research
-
Regulation of HDAC6 catalytic activity in cancer: the role of post-translational modifications and protein–protein interactions
Asaad, L., Pepperrell, B., McErlean, E. & Furlong, F., 01 Feb 2025, In: International Journal of Molecular Sciences. 26, 3, 23 p., 1274.Research output: Contribution to journal › Review article › peer-review
Open AccessFile5 Downloads (Pure) -
Human epididymis protein 4 (HE4) in the pulmonary microenvironment: A window into fibrosis
Reid, A., McKelvey, M., Yakkaluru, K., Hunter, C., Khawaji, A. A. S., Furlong, F., Potel, K. N. & Schock, B., 13 Nov 2024, In: Irish Journal of Medical Science. 196, Suppl 6, p. S227 1 p.Research output: Contribution to journal › Meeting abstract › peer-review
-
Hollow microneedle assisted intradermal delivery of hypericin lipid nanocapsules with light enabled photodynamic therapy against skin cancer
Abd-El-Azim, H., Tekko, I. A., Ali, A., Ramadan, A., Nafee, N., Khalafallah, N., Rahman, T., Mcdaid, W., Aly, R. G., Vora, L. K., Bell, S. J., Furlong, F., McCarthy, H. O. & Donnelly, R. F., Aug 2022, In: Journal of Controlled Release. 348, p. 849-869 21 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile65 Citations (Scopus)170 Downloads (Pure) -
Investigation of synergistic drug combinations involving HDAC6 inhibition and anti-cancer agents in triple negative breast cancer
Wang, Y., Zhang, F., Khawaji, A. A. S., Asaad, L. & Furlong, F., 30 Mar 2022.Research output: Contribution to conference › Poster › peer-review
-
To investigate the modulation of HDAC6 activity by the extracellular matrix in triple negative breast cancer cells
Asaad, L., Zhang, F., Wang, Y., Burrows, J., Abdullah, Q. & Furlong, F., 30 Mar 2022.Research output: Contribution to conference › Poster › peer-review
Prizes
-
Actin Cytoskeleton Rearrangement in Mesangial Cells. Novel implications of TGF-beta Signalling in Diabetic Nephropathy
Furlong, F. (Recipient), 2005
Prize: Prize (including medals and awards)
-
Downregulation of MAD2 renders cancer cells resistant to Paclitaxel
Furlong, F. (Recipient), 2008
Prize: Prize (including medals and awards)
-
microRNA Regulation of the Spindle Assembly Checkpoint (SAC): Implications for Cell Cycle Dysregulation in Ovarian Cancer and Taxol Responsiveness.
Furlong, F. (Recipient), 2008
Prize: Fellowship awarded competitively
-
Predicting chemo-response in serous papillary epithelial ovarian cancer (EOC)
Furlong, F. (Recipient), 2011
Prize: Prize (including medals and awards)
-
Unlocking the individualised response to chemotherapy in triple negative breast cancer
Furlong, F. (Recipient), 2010
Prize: Prize (including medals and awards)
Activities
-
57th Irish Association for Cancer Research Conference 2021
Furlong, F. (Member of the organising committee)
24 Mar 2021 → 26 Mar 2021Activity: Participating in or organising an event types › Participation in conference
-
The extracellular Matrix: A Target in Breast Cancer Treatment and Prognosis
Furlong, F. (Examiner)
11 Nov 2020Activity: Examination types › PhD external examination
-
56th Irish Association for Cancer Research Conference 2020
Furlong, F. (Member of the organising committee)
26 Feb 2020 → 28 Feb 2020Activity: Participating in or organising an event types › Participation in conference
-
ERNEST COST Action Conference: GPCR Pharmacology: activation, signalling and drug design 2019
Furlong, F. (Participant)
28 Oct 2019 → 30 Oct 2019Activity: Participating in or organising an event types › Participation in conference
-
11th TCD International Cancer Conference 2019
Furlong, F. (Participant)
24 Sept 2019 → 25 Sept 2019Activity: Participating in or organising an event types › Participation in conference